CL stock · EDIT stock

CL vs EDIT

Colgate-Palmolive Company (CL) versus Editas Medicine Inc (EDIT) — a side-by-side from cached financials, not a winner call.

Colgate-Palmolive Company (CL) is a household & personal products company listed on US.

Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.

Latest reported CL revenue for 2025-12-31 was $20.38B. Net income was $2.13B. Revenue was up 1.4% from 2024-12-31 to 2025-12-31. CL currently screens at market cap $70.88B and trailing P/E 34.3.

Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.

CL currently screens at market cap $70.88B and trailing P/E 34.3. EDIT currently screens at market cap $375.2M.

Not investment advice. Open the CL and EDIT stock pages for the full models.

Not investment advice.

Popular Stock Comparisons